178 related articles for article (PubMed ID: 30935497)
1. [Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil].
Almeida da Silva HC; Ferreira G; Rodrigues G; Santos JMD; Andrade PV; Hortense A; Vaz Perez M; Amaral JLGD
Braz J Anesthesiol; 2019; 69(2):152-159. PubMed ID: 30935497
[TBL] [Abstract][Full Text] [Related]
2. [Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia].
Silva HCAD; Onari ES; de Castro I; Perez MV; Hortensi A; Amaral JLGD
Braz J Anesthesiol; 2019; 69(4):335-341. PubMed ID: 31053363
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
[TBL] [Abstract][Full Text] [Related]
4. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
Ginz HF; Girard T; Censier K; Urwyler A
Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
[TBL] [Abstract][Full Text] [Related]
6. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
[TBL] [Abstract][Full Text] [Related]
7. In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?
Metterlein T; Schuster F; Kranke P; Roewer N; Anetseder M
Eur J Anaesthesiol; 2011 Apr; 28(4):251-5. PubMed ID: 20827211
[TBL] [Abstract][Full Text] [Related]
8. [Malignant hyperthermia].
Glahn KP
Ugeskr Laeger; 2003 Apr; 165(17):1763-8. PubMed ID: 12768904
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
10. Malignant hyperthermia.
Ben Abraham R; Adnet P; Glauber V; Perel A
Postgrad Med J; 1998 Jan; 74(867):11-7. PubMed ID: 9538480
[TBL] [Abstract][Full Text] [Related]
11. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.
Larach MG; Landis JR; Bunn JS; Diaz M
Anesthesiology; 1992 Jan; 76(1):16-27. PubMed ID: 1729931
[TBL] [Abstract][Full Text] [Related]
12. Abnormal calcium signalling and the caffeine-halothane contracture test.
Figueroa L; Kraeva N; Manno C; Toro S; Ríos E; Riazi S
Br J Anaesth; 2019 Jan; 122(1):32-41. PubMed ID: 30579404
[TBL] [Abstract][Full Text] [Related]
13. Malignant hyperthermia.
Rosenberg H; Davis M; James D; Pollock N; Stowell K
Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
[TBL] [Abstract][Full Text] [Related]
14. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
15. [Modern diagnostic approaches to malignant hyperthermia susceptibility].
Kazantseva AA; Lebedinskiĭ KM
Anesteziol Reanimatol; 2014; 59(4):64-8. PubMed ID: 25549489
[TBL] [Abstract][Full Text] [Related]
16. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
[TBL] [Abstract][Full Text] [Related]
17. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
Krivosic-Horber R; Adnet P; Guevart E; Theunynck D; Lestavel P
Br J Anaesth; 1987 Dec; 59(12):1554-6. PubMed ID: 3426910
[TBL] [Abstract][Full Text] [Related]
19. In vitro contracture testing for determination of susceptibility to malignant hyperthermia: a methodologic update.
Iaizzo PA; Wedel DJ; Gallagher WJ
Mayo Clin Proc; 1991 Oct; 66(10):998-1004. PubMed ID: 1833602
[TBL] [Abstract][Full Text] [Related]
20. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane.
Snoeck MM; Gielen MJ; Tangerman A; van Egmond J; Dirksen R
Acta Anaesthesiol Scand; 2000 Mar; 44(3):334-7. PubMed ID: 10714850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
